Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning

Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning

Seasoned Manufacturing Executive Joins Manufacturer of Therapeutic Proteins

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Jul 19, 2010 - Phage Pharmaceuticals, Inc., a clinical-stage developer and manufacturer of therapeutic proteins, announced today that it has appointed David Jackson to the position of Vice President, Operations Planning. In this role, Mr. Jackson is responsible for oversight of the company's cGMP-certified therapeutic protein manufacturing facility in San Diego. He reports to Robert J. Beckman, CEO of Phage Pharmaceuticals.

Prior to joining Phage Pharmaceuticals, Mr. Jackson was the Vice President of Process Development and Manufacturing at VaxInnate Corporation, where he was responsible for creating Development, QA/QC, and Regulatory teams, and as well as for building the company's infrastructure and overseeing capital projects. He previously was VP of U.S. Operations and later VP of Global Biologics Manufacturing at Lonza Biologics Inc., a wholly-owned subsidiary of Lonza Group Ltd. (Switzerland), where he was responsible for green-field site construction and other capital projects, as well as technology transfer and GMP contract manufacturing. He also served as VP of Manufacturing at BioReliance Corporation and VP of Manufacturing and Pharmaceutical Support at EntreMed, Inc. Mr. Jackson served honorably in the United States Marine Corps and received a B.A. in Chemistry from Olivet Nazarene University.

About Phage Pharmaceuticals

Phage Pharmaceuticals makes use of a proprietary production method that improves upon well-established approaches for the manufacture of targeted proteins and results in the production of properly-folded therapeutic proteins at high yields. The production method results in lower manufacturing costs with fewer waste by-products and impurities compared with current conventional methods used in the manufacture of similar therapeutics.

Phage Pharmaceuticals has two product candidates in clinical development, Human Growth Hormone ("hGH") and Fibroblast Growth Factor-1 ("FGF-1"). Both product candidates have open, active INDs with the FDA. Phase I clinical trials of the company's hGH drug candidate have been completed successfully, and the company is positioned to begin further clinical development of hGH as a biosimilar. FGF-1 manufactured at Phage Pharmaceuticals' facilities has been assessed successfully in a Phase I clinical trial for treatment of wounds and was shown to be safe and well-tolerated. Other preparations of FGF-1 prepared in Phage Pharmaceuticals' facilities in the same manner were assessed in Phase I safety and Phage II efficacy trials for the treatment of severe Coronary Heart Disease. Phage Pharmaceuticals has other therapeutic proteins in various stages of pre-clinical development. Among the programs are those involving Beta Interferon, G-CSF, Parathyroid Hormone, EGF, the various forms of FGF (1 to 22), and pegylated versions of Interferon Alpha, hGH, C-CSF, Beta Interferon, EPO, Coagulation Factor VIII, Coagulation Factor IX, FGF-1, Interferon Gamma, Interleukin-12, and Insulin-Like Growth Factor-1.

 

 

Contact: Phage Pharmaceuticals, Inc.
Philip N. Sussman, 212-330-8076
Chief Business Officer
[email protected]

 

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.